ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO751

Results From a Phase 1 Study Demonstrating the Safety and Pharmacokinetics of the Aldosterone Synthase Inhibitor CIN-107 in Subjects With Varying Degrees of Renal Function

Session Information

Category: Hypertension and CVD

  • 1502 Hypertension and CVD: Clinical‚ Outcomes‚ and Trials


  • Freeman, Mason W., CinCor Pharma, Inc., Waltham, Massachusetts, United States
  • Halvorsen, Yuan-Di, CinCor Pharma, Inc., Waltham, Massachusetts, United States
  • Bond, Mary, CinRx Pharma, LLC, Cincinnati, Ohio, United States
  • Murphy, Brian, CinRx Pharma, LLC, Cincinnati, Ohio, United States
  • Isaacsohn, Jonathan, CinRx Pharma, LLC, Cincinnati, Ohio, United States

Hypertension and chronic kidney disease are common comorbidities exacerbated by elevated aldosterone. CIN-107 is a selective inhibitor of aldosterone synthase with the potential to lower blood pressure and slow the progression of kidney disease. This phase 1 open-label study assessed the safety and pharmacokinetics (PK) of a single oral dose of CIN-107 in subjects with varying degrees of renal function.


Subjects enrolled into renal function groups based on estimated glomerular filtration rate (eGFR). The groups were control (eGFR ≥60mL/min), moderate to severe renal impairment (eGFR 15 to 59 mL/min), and kidney failure (eGFR <15mL/min, including subjects on dialysis). A single 10 mg CIN-107 dose was given, followed by 7 days of PK sampling (blood and urine). Safety was assessed based on adverse events, clinical laboratory evaluations, vital signs, ECGs, physical examinations, and weight measurements.


32 subjects completed the study. There were no deaths, and only one mild drug-related adverse event (diarrhea) occurred. There were no clinically meaningful changes in laboratory values, vital signs, physical examinations, or ECGs. The plasma concentration-time curves of CIN-107 in all groups were qualitatively similar (Figure 1). The urine PK parameters in the moderate to severe renal impairment group were similar to control (12% excreted); however, inadequate urine production in the kidney failure group resulted in negligible excretion of CIN-107.


A single dose of CIN-107 was well tolerated in all subjects, including those with kidney failure. Renal impairment did not significantly impact systemic exposure or clearance of CIN-107, suggesting that dose adjustment due to PK differences in these patients is unnecessary, even in cases of advanced kidney disease.

Plsma 107 Concentr vs Time


  • Commercial Support – CinCor Pharma, Inc.